ENTITY
CanSino Biologics

CanSino Biologics (688185 CH)

112
Analysis
Health Care • China
CanSino Biologics Inc. develops and manufactures biological vaccine products. The Company discovers quadrivalence meningococcal conjugate, pneumococcal polysaccharide, and adenovirus vector-based tuberculosis vaccines for human use. CanSino Biologics serves customers worldwide.
more
bullish•Cross Asset Strategy
•12 Jan 2023 11:01•Syndicated

CX Daily: Why Countries Are Putting Curbs On Travelers From China

Caixin Explains: Why countries are putting curbs on travelers from China. Henan village banks start reimbursing large depositors

Logo
620 Views
Share
bullish•Cross Asset Strategy
•06 Sep 2022 09:45•Syndicated

CX Daily: China’s Steel Industry at a Crossroads as Long Winter Looms

Cover Story: China’s steel industry at a crossroads as long winter looms. 33 cities in China are under some sort of lockdown

Logo
385 Views
Share
bullish•Cross Asset Strategy
•31 Aug 2022 09:57•Syndicated

CX Daily: Washington’s Drive to Hobble Chinese Chipmaking

Caixin Explains: Washington’s drive to hobble Chinese chipmaking. Communist Party’s 20th National Congress to kick off on Oct. 16

Logo
282 Views
Share
bullish•Cross Asset Strategy
•07 Apr 2022 10:32•Syndicated

CX Daily: China Turns to Credit Easing to Kick-Start Sluggish Economy

In Depth: China turns to credit easing to kick-start sluggish economy. Shanghai reverses Covid separation policy to let families stay with their...

Logo
280 Views
Share
x